What We're Reading: Page 175
Industry reads hand-picked by our editors
Sep 23, 2020
-
The Wall Street Journal
Draft Guidelines Say Covid-19 Vaccine to Require Strict Review for Authorization
-
STAT
MIT researcher held up as model of how algorithms can benefit humanity
-
The New York Times
Coronavirus Vaccine Trials Could Suffer From Shortcuts
-
FiercePharma
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Sep 22, 2020
Sep 21, 2020
-
BioCentury
Controversy over Azar memo highlights concerns about politicization of FDA
-
The New York Times
A Deal on Drug Prices Undone by White House Insistence on ‘Trump Cards'
-
STAT
Black doctors' group creates panel to vet Covid-19 vaccines
-
Evaluate Vantage
Esmo 2020 puts Opdivo and Cabometyx back in the game
Sep 18, 2020
Sep 17, 2020
-
Reuters
Delaware judge deals Biogen another blow in Tecfidera patent fight
-
Bloomberg
HHS Steered $700 Million From CDC to Fund Warp Speed Program
-
MM&M
Behind ‘the apology’: Wayne Pines, who counseled FDA Commissioner Hahn to clarify plasma remarks, addresses the controversy
-
Endpoints News
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Sep 16, 2020
-
Reuters
U.S. FDA's Hahn plans 'significant' work with AstraZeneca in COVID-19 trial inquiry
-
Bloomberg
Illumina Nears Deal to Buy Health-Care Startup Grail
-
Endpoints News
A month after losing its lead program, Unity Biotechnology cuts 30% of staff in restructuring
-
The Wall Street Journal
How Biotech Investors Can Survive Election Season
Sep 15, 2020
-
Kaiser Health News
NIH 'Very Concerned' About Serious Side Effect in Coronavirus Vaccine Trial
-
The Wall Street Journal
Kodak Deal Draws Review From Watchdog at Agency Involved in Planned Loan
-
Reuters
Marinus genetic epilepsy drug meets main goal of late-stage study
Previous
